By combining our robust internal discovery capabilities with our ability to identify and establish effective collaborations, we’ve created a powerful discovery engine to build an expanded pipeline of biotherapeutics, including antibody-drug conjugates (ADCs), and innovative small molecules.
Small molecule drug discovery: Past success inspires future potential
Our small molecule legacy began with the discovery of our franchise molecule, cabozantinib, which has been successfully commercialized in multiple cancer indications and countries. We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery.
Cabozantinib | Zanzalintinib | XL102
Biotherapeutics: A new dimension of our pipeline
Much of our drug discovery activities focuses on discovering and advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. Several biotherapeutic product candidates have progressed into clinical trials.
+ Cybrexa Therapeutics and Exelixis have an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12
* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805